Colgate-Palmolive (CL) Q2 2026 earnings review
Margin Reversal Powers a Guidance Upgrade
Colgate-Palmolive delivered a decisive Q2 beat, proving its pricing power and productivity initiatives can outrun inflation. Net sales grew 4.9% to $5.36B, while organic sales grew 2.4%. The real story is profitability: reversing the dire cost-inflation narrative from Q1, gross margins expanded 140 basis points to 61.5%. Management capitalized on this momentum by upgrading full-year guidance for both gross margin and Base Business EPS. While North America remains a glaring volume laggard, massive strength in Latin America and robust global pricing power make this a highly encouraging quarter.
🐂 Bull Case
Despite a massive $300M commodity and logistics headwind flagged in Q1, Colgate expanded Q2 gross margins by 140 bps year-over-year. The Strategic Growth and Productivity Program (SGPP) is delivering tangible bottom-line results faster than anticipated.
Latin America—which accounts for 26% of company sales—saw operating profit surge 14% on 13.7% net sales growth, driven by a highly profitable mix of 2.6% volume growth and 2.8% pricing.
🐻 Bear Case
The turnaround in the company's home market is failing to materialize. North American organic volume plummeted 3.9% year-over-year, marking an acceleration in volume decay compared to Q1's -3.2%.
Hill's Pet Nutrition volume contracted 1.2% (organic volume -1.8%). Even accounting for the strategic exit from low-margin private label products, premium pet food is facing demand destruction in a sluggish macro category.
⚖️ Verdict: 🟢
Bullish. When a company can face significant global inflation, aggressively increase advertising spend by 15%, and still upgrade its full-year EPS and margin guidance, the underlying operating model is exceptionally healthy. The NA weakness is the only major blemish on a pristine print.
Key Themes
The Great Margin Reversal
Reversing the bearish tone of Q1—where management cut margin expectations due to an estimated $300M in new raw material costs—Q2 delivered a massive upside surprise. GAAP gross margins hit 61.5% (up 140 bps). The company successfully passed through pricing (+1.6% globally) and reaped the initial rewards of its expanded SGPP restructuring. This allowed management to officially reverse its FY26 gross margin guidance from 'down' to 'roughly flat'.
Aggressive Brand Reinvestment
Colgate isn't hoarding its margin gains; it is pouring them back into demand generation. Advertising expense surged 15% year-over-year to $777M in Q2. Year-to-date, the company has spent $1.51B on advertising compared to $1.35B last year. This omnichannel demand generation strategy is critical to sustaining organic growth in a persistently sluggish global consumer environment.
North America Volume Drain Deepens
The turnaround in North America (17% of total sales) remains a heavy drag. Organic volume decelerated further, dropping 3.9% in Q2 following a 3.2% decline in Q1. While operating profit crept up 3%, it was entirely fueled by pricing (+0.9%) and SGPP cost cuts. The company is bleeding unit market share in its home territory to aggressive competitor couponing.
Latin America Carries the Top Line
Latin America continues to operate in a different stratosphere than developed markets. Q2 net sales jumped 13.7%, powered by a balanced attack of volume (+2.6%), pricing (+2.8%), and a favorable FX tailwind (+8.4%). Operating profit margin in the region hit an elite 30.4%.
Hill's Growth Exclusively Price-Driven
Hill's Pet Nutrition posted 3.4% reported growth, but the underlying mechanics are weakening. Organic volume declined 1.8%, masked entirely by aggressive 3.9% pricing actions. Even factoring in the 0.6% negative volume impact from exiting the private-label business, the premium pet segment is showing signs of consumer fatigue and unit elasticity.
Other KPIs
Operating cash flow accelerated 17% year-over-year, up from $1.48B in the first half of 2025. This robust cash generation easily covered $879M in dividends and funded $597M in share repurchases, proving the company's cash engine remains highly insulated from macro volatility.
Non-GAAP EPS accelerated 8% year-over-year, comfortably beating the previous trajectory. GAAP EPS ($0.86) was artificially suppressed by a $129M restructuring charge tied to the new Strategic Growth and Productivity Program.
Guidance
Reversing. In Q1, management spooked investors by projecting gross margins would be 'down' for the year due to $300M in raw material inflation. The Q2 outperformance allowed them to walk this back to 'roughly flat,' signaling immense confidence in back-half cost controls and pricing retention.
Accelerating. Upgraded from the prior 'low- to mid-single-digit growth' framework. This confirms that the SGPP restructuring savings and Q2 margin expansion will drop straight to the bottom line.
Stable. The company maintained its prior organic growth band. Given the 2.9% growth in Q1 and 2.4% in Q2, they are pacing comfortably near the midpoint, absorbing the 20-30 bps headwind from the pet food private-label exit.
Key Questions
North America Volume Contraction
With North American organic volumes decelerating to -3.9% this quarter, pricing is doing all the heavy lifting. How long can you sustain profit growth in this division before unit share losses become structurally damaging?
The Gross Margin Whiplash
In Q1, you guided FY gross margins down based on an estimated $300M in raw material and logistics headwinds. One quarter later, you've expanded margins 140 bps and upgraded the year. Did commodity inputs suddenly collapse, or did SGPP and RGM completely neutralize the threat much faster than modeled?
Hill's Pet Nutrition Elasticity
Organic volume at Hill's declined 1.8%, while pricing was up 3.9%. Excluding the known headwinds of the private label exit, are you seeing consumer trade-down out of the premium/therapeutic tiers as pricing fatigue sets in?